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Abstract
Background Five-aminolevulinic acid (Gliolan, medac,
Wedel, Germany, 5-ALA) is approved for fluorescence-
guided resections of adult malignant gliomas. Case reports
indicate that 5-ALA can be used for children, yet no prospec-
tive study has been conducted as of yet. As a basis for a study,
we conducted a survey among certified European Gliolan
users to collect data on their experiences with children.
Methods Information on patient characteristics, MRI charac-
teristics of tumors, histology, fluorescence qualities, and out-
comes were requested. Surgeons were further asked to indi-
cate whether fluorescence was “useful”, i.e., leading to
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changes in surgical strategy or identification of residual tumor.
Recursive partitioning analysis (RPA) was used for defining
cohorts with high or low likelihoods for useful fluorescence.
Results Data on 78 patients <18 years of age were submitted
by 20 centers. Fluorescence was found useful in 12 of 14
glioblastomas (85 %), four of five anaplastic astrocytomas
(60 %), and eight of ten ependymomas grades II and III
(80 %). Fluorescence was found inconsistently useful in
PNETs (three of seven; 43 %), gangliogliomas (two of five;
40 %), medulloblastomas (two of eight, 25 %) and pilocytic
astrocytomas (two of 13; 15 %). RPA of pre-operative factors
showed tumors with supratentorial location, strong contrast
enhancement and first operation to have a likelihood of useful
fluorescence of 64.3 %, as opposed to infratentorial tumors
with first surgery (23.1 %).
Conclusions Our survey demonstrates 5-ALA as being used
in pediatric brain tumors. 5-ALA may be especially useful for
contrast-enhancing supratentorial tumors. These data indicate
controlled studies to be necessary and also provide a basis for
planning such a study.
Keywords 5-ALA . Gliolan . Pediatric brain tumor .
Medulloblastoma . Ependymoma . Glioblastoma . Anaplastic
astrocytoma . Fluorescence-guided resection
Introduction
Five-aminolevulinic acid (5-ALA, Gliolan) is approved for
fluorescence-guided resections of malignant gliomas in Europe
and a number of countries abroad. Approval of 5-ALA was
based on a randomized study in adults and is now commonly
used [1–10]. ALA induces the accumulation of fluorescent
protoporphyrin IX (PpIX) in malignant gliomas via the heme
biosynthesis pathway. This fluorochrome can be visualized intra-
operatively and is useful for the identification of residual tumor.
Since its approval in 2007, numerous reports have appeared also
describing possible uses of 5-ALA in tumors other than gliomas,
such as meningiomas, metastases, and others [11–13].
Inmany pediatric brain tumors, safe maximal resections have
also been linked to prognosis [14–20], and it has always been of
interest whether 5-ALAwould be useful in this patient popula-
tion. However, the histologist encountered in typical intra-axial
contrast-enhancing tumors in children are much more varied
than in adults. Apart from the malignant gliomas, in which 5-
ALA has an established track record in adults, pediatric tumors
include primitive neuroectodermal tumors, ependymomas,
pilocytic astrocytomas, medulloblastomas, and others. Little is
known about the extent of PpIX accumulation and fluorescence
after 5-ALA administration in these childhood tumors and
whether this fluorescence is actually useful for surgery, thus
justifying any risks involved in 5-ALA application. No con-
trolled studies have been performed so far. Two case reports
describe useful fluorescence in a pleomorphic astrocytoma [21],
the other in a medulloblastoma [22]. In addition, Preuss et al.
[23] published a compilation of 18 children operated on with
Gliolan in a compassionate-use setting compiled from three
neurosurgical centers in Germany and France and covering a
variety of pediatric brain tumor pathologies. Results were equiv-
ocal as only eight of 14 tumors displayed fluorescence, which
was in turn considered to be “useful” in only seven children
(three glioblastomas, one pleomorphic neuroectodermal tumor,
one ependymoma III, one anaplastic astrocytoma, and one
pilocytic astrocytoma). In a further small series of three case
reports, useful fluorescence was found in two glioblastoma, but
not in a case of medulloblastoma [24], underlining ambiguous
findings. In addition, more recently, another series was pub-
lished, this time discussing the use of 5-ALA in 16 children
operated on at a single center outside the framework of a
controlled clinical trial and with an undefined source of 5-
ALA [25]. The youngest child in this series was 1 year old.
Again, a variety of different pediatric tumors was observed with
5-ALA apparently inducing fluorescence in only three of 16
children (one anaplastic astrocytoma, one pilocytic astrocytoma,
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one glioblastoma). The question of whether this fluorescence
was truly helpful was not addressed. On the other hand, distinct
increases in liver enzymes in response to 5-ALAwere observed,
such as an increase of alanine aminotransferase (ALT). This was
more evident more in younger children [25].
Especially this last series cautions that there is uncontrolled
use of 5-ALA outside of clinical trials in children, despite
possible side-effects and potential limitations due to the many
different brain tumor types that will potentially be treated.
These observations strongly underline the necessity for a
controlled clinical trial of Gliolan in children with an emphasis
on safety. However, since all results so far were rather ambig-
uous, it appeared wise to collect further data before planning
such a trial. For this reason, certified Gliolan users throughout
Europe were asked to submit their anonymous data on chil-
dren operated in their centers in an off-label setting. The
collected information was intended to create a larger database
with the aim of identifying those children pre-operatively
which might benefit from 5-ALA, in order to design a future
controlled study.
Methods
This retrospective survey on children and juveniles <18 years
of age was based on a structured questionnaire that was
Table 1 Characteristics of chil-
dren stratified by resection status Characteristic All Primary Recurrent p value
n 78 45 33
Age (years)
± SD average 12.0±4.39 12.3±4.67 11.7±3.94 t test: 0.50
Range 1.6–17 4–17 1.6–18
Median 13 14 12
Sex
Female (n) 27 14 13 Chi2: 0.48
Male (n) 51 31 20
KPS
Median 90 90 90
Range 30–100 60–100 30–100 Chi2: 0.89
<=60 n (%) 12 (15.4) 6 (13.6) 6 (17.6)
70–80 17 (21.8) 10 (22.7) 7 (20.6)
90–100 49 (62.8) 28 (63.6) 21 (61.8)
Weight (kg)
Avg±SD 44.2±19.4 45.2±20.5 42.8±17.8 t test: 0.61
Median 42.4 42.5 42.4
Range 11–95 11.9–82 11–82
Fig. 1 Distribution of ages for
the complete cohort and stratified
by recurrence status
Acta Neurochir (2014) 156:2315–2324 2317
distributed to Gliolan users throughout Europe who partici-
pate in the Gliolan riskmanagement programmandated by the
European Medicines Agency (EMA). This questionnaire re-
quired the following information:
& Patient characteristics: age, sex, weight, Karnofsky Per-
formance Score (KPS)
& Preoperative symptoms (nausea, vomiting, seizures, atax-
ia, paresis, visual symptoms, other)
& Dosing information (dose, time of application prior to
anesthesia)
& Preoperative magnetic resonance imaging (MRI) data
Location (intra- or extra-axial, supra- or infratentorial)
Degree of contrast enhancement (strong, weak/patchy,
none)
& Recurrence status (yes or no)
& Preoperative symptoms
& Final histology
& Quality of fluorescence (strong, weak/patchy, none)
& “Usefulness” of 5-ALA, defined as a change in surgical
strategy or identification of residual tumor based on 5-
ALA fluorescence
& Resection status
& Adverse events or lack thereof
Twenty centers provided their data. No source data verifi-
cation was performed for this study.
As all children were treated in an off-label setting and this
was a retrospective cohort study, ethical committee approval
was not acquired from any of the participants prior to off-label
administration of Gliolan. Contributing surgeons indicate hav-
ing obtained informed consent in all cases. Since all
participating physicians were certified in the context of the
European Risk Management Plan, experience in each center
was high and patients were generally treated in accordance
with the general principles recommended for the use in adults,
i.e., application of 20 mg/kg body weight orally and post-
operative light protection for 24 h.
Data on children published in the three-center compilation
by Preuss et al. [23] were included in this investigation using
the structured questionnaire.
Statistics
Univariate and multivariate logistic regression analyses were
performed for testing interrelationships between factors. The
Chi-squared test was used for testing contingency tables of
nominal data and the t test for comparing numerical data.
Recursive partitioning analysis (RPA) was used for defining
subgroups with/without the likelihood of having “useful”
fluorescence. All statistical analyses, including RPA analysis,
were performed using JMP statistics software (version
11.1.1).
Results
Children’s demographic characteristics are given in Table 1.
Figure 1 details the distribution of the children’s ages. The
median age was 13, the median KPS was 90, and the median
weight 42.4 kg. The most common preoperative symptom
was “headache” (30/78; 38.4 %), followed by “nausea/
vomiting” (20/78, 25.6 %), visual symptoms (13/78,
16.7 %), “paresis” (9/78, 11.5 %), and ataxia (8/78, 10.2 %).
“Other symptoms” included changes in personality,
Fig. 2 Distribution of
administration time of complete
cohort, stratified by recurrence
status
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somnolence (n=2), drowsiness, loss of fine movements of
hand, nystagmus, abducens nerve paresis (n=2), neck pain,
walking disability, facial nerve paresis, anisocoria, hydroceph-
alus, fatigue, aphasia, and dyslexia.
All children were given 20 mg/kg Gliolan orally dissolved
in tap water. However, there was a wide variation in timing of
application of 5-ALA solution prior to surgery, as detailed in
Fig. 2. Solutions were generally administered between 2 and
4 h prior to surgery. A distinct group of children was given
solution at 6 h prior to surgery.
Apart from fluorescence, other methods for location of
tumor were used intra-operatively, with neuronavigation
employed in 57 of 78 (73.1 %) cases, ultrasound in 35 of 78
(44.9 %) cases, and intra-operative CT in one case. Mapping/
monitoring techniques were used in 17 of 78 children (21.8 %).
As expected, the variability of different tumors that were
considered amenable to fluorescence-guided resection prior to
surgery was high. The most frequent tumors were glioblasto-
mas, followed by anaplastic astrocytomas, ependymomas
grade III, PNETs, gangliogliomas, medulloblastomas, and
pilocytic astrocytomas. These seven entities accounted for
59 of 78 tumors (>4 patients, Table 2). All of these tumors
showed contrast enhancement to a variable extent on MRI.
Fluorescence, however, was inconstant and was found to be
useful in only 28 of these patients, the least commonly in
medulloblastomas and pilocytic astrocytomas and inconsis-
tently in gangliogliomas and PNETs. Among the infrequent
entities found in this series (<4 patients, Table 3), all three
ependymomas grade II showed useful fluorescence (Fig. 3). It
was notable that the only meningiomas in this group also
revealed useful fluorescence, as well as did a meningeal
sarcoma.
For practical use, it would be of value to determine factors
ex ante for predicting useful fluorescence before applying 5-
ALA. To identify such factors, single and multiple factor
nominal-logistic regression analysis was performed (Table 4).
For this analysis, two children with spinal tumors (one lipoma,
one pilocytic astrocytoma) were omitted. Neither a single nor
a combination of multiple factors was found to significantly
predict the accumulation of “useful” fluorescence. However,
there was a tendency for location (supra-, infratentorial) re-
currence status (recurrence yes/no) and contrast enhancement
on the pre-operative MRI to predict “usefulness”.
Recursive partition analysis (RPA) was employed using
these factors in order to better understand the interaction
between these factors and the criterion “usefulness”. RPA
generated a decision tree with five terminal nodes after three
splits with different groups of patients characterized by vary-
ing likelihoods for the “usefulness” of fluorescence. Useful-
ness was highest in patients with tumors located
supratentorially, strong contrast enhancement on MRI, and
first surgery (64.3 %) as compared to patients with
infratentorial tumors and first surgery (23.1 %, Fig. 4). Ta
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“Complete” resections on post-operative MRI were docu-
mented in 62 patients (79.5 %; one missing). However, there
was no significant relationship between fluorescence manifes-
tation, usefulness of fluorescence, and completeness of
resection.
Table 5 summarizes adverse events reported in this study.
Study participants reported no toxicological adverse events
and in the majority of cases, no neurological adverse events
were given. However, adverse events were recorded in eight
of 78 patients (Table 5). In four of these patients, either
weak/patchy or strong fluorescence was found, resulting in
“useful” fluorescence in only two patients, one with post-
operative hygroma after resection of a grade II
ependymoma, and one with transient hoarseness after resec-
tion of a grade III ependymoma of the posterior fossa. In
one patient (recurrence for medulloblastoma), unspecific
fluorescence was found in gliotic tissue. Unspecific fluores-
cence was also described in one patient with recurrent
oligodendroglioma grade III. In both cases, fluorescence
was characterized as weak/patchy.
Table 3 Pre-operative contrast enhancement, intra-operative fluorescence characteristics, and “usefulness” of fluorescence in tumors with
a frequency <4 in this cohort
Subgroup n First
surgery
Recurrence Strong
c+
Weak/
patchy c+
No
c+
Supratentorial Infratentorial Strong flu Weak/
patchy flu
No
flu
Useful
flu n (%)
Ependymoma II 3 0 3 3 0 0 2 1 2 1 0 3 (100)
Oligodendroglioma II 2 2 0 0 2 0 2 0 1 0 1 1 (50)
Oligodendroglioma III 2 1 1 2 0 0 2 0 0 1 1 0 (0)
DNET 2 2 0 1 1 0 2 0 1 0 1 1 (50)
PXA II 2 1 1 1 0 1 2 0 0 0 2 0 (0)
DA II 1 1 0 0 1 0 1 0 0 1 0 0 (0)
Glioneural tumor IVth
ventricle
1 1 0 0 1 0 0 1 0 1 0 1 (100)
Plexus papilloma II 1 0 1 0 1 0 1 0 0 0 1 0 (0)
Papillary meningiomas 1 0 1 1 0 0 1 0 1 0 0 1 (100)
Lipoma 1 1 0 0 1 0 0 1* 0 0 1 0 (0)
Neuroblastoma metastasis 1 1 0 0 1 0 1 0 0 0 0 0 (0)
Meningeal sarcoma 1 1 0 1 0 0 1 0 1 0 0 1 (100)
Gliotic tissue (after
medulloblastoma surgery)
1 0 1 0 1 0 0 1 0 1 0 0 (0)
Abbreviations: c+: contrast enhancement on MRI; flu.: visible fluorescence
*Spinal intramedullary location
Fig. 3 Example of fluorescence
in ependymoma grade II (female,
12 years of age). Top left: blue
light image of typical red
fluorescence characterized as
strong and related to
ependymoma tissue (Zeiss
Pentero); top right:
Corresponding white light image.
Bottom left: preoperative MRI
showing tumor of 4th ventricle
with patchy contrast-
enhancement; middle: blue light
image of tissue specimen; right:
corresponding white light image
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Discussion
Gliolan (5-ALA) is approved for fluorescence-guided resections
of malignant gliomas in Europe and other countries in adults but
not in children. Thus, any use in children is strictly off-label. In
this patient population, a general recommendation for the use of
5-ALA cannot be given and thus should be restricted to selected
cases, since the safety profile has not been established, especial-
ly in young children. Nevertheless, there is now indication from
the literature that 5-ALA appears to be used in several centers on
an off-label basis despite the absence of data from controlled
studies, especially on safety. In addition, the methods of appli-
cation are not standardized and even in the present series the
timing of administration varied widely. This is an undesirable
development. Obviously, controlled studies are needed to deter-
mine both whether 5-ALA is toxicologically safe in children
and whether 5-ALA is useful for facilitating detection or visu-
alization of typical pediatric brain tumors.
In contrast to adults, the spectrum of brain tumor types is
much broader in children. Not all tumor types may be good
candidates for 5-ALA fluorescence-guided resections, even
when they are intra-axial and show contrast enhancement on
MRI. Especially pilocytic astrocytomas of the posterior fossa
may be strongly enhancing and in some cases may be con-
fused for medulloblastomas from imaging alone. Since they
are benign in nature and usually well circumscribed intra-
operatively, they may not be suitable for fluorescence-
guided resections.
Schwake et al. [26] have demonstrated that cultures of cells
derived from childhood brain tumors show differences in vitro
regarding the level and the time course of PpIX accumulation.
Medulloblastoma, PNET, and malignant glioma cell lines all
showed variable results. Similar differential accumulation has
been observed in medulloblastoma cell lines by others [27].
These observations alone question the expectation that pedi-
atric brain tumors, even if malignant, will uniformly show
useful fluorescence.
Thus, designing a study for the use of 5-ALA in children
requires careful planning regarding which types of potential
tumors to include. Since the available data collected and
published so far are restricted, we set out to compile cases of
children treated by European Gliolan users certified in the
context of the Risk Management Plan imposed by EMA.
The resulting series is the largest to date with a collection of
78 children, now allowing more distinct conclusions regard-
ing the usefulness of 5-ALA in this patient population, when
5-ALA is used in the same dosage and with comparable
timing as compared to the adult population.
The results show glioblastomas and anaplastic astrocyto-
mas to be similarly amenable to fluorescence-guided resec-
tions as in adults. It was interesting to determine that nine of
ten ependymomas, regardless of whether they were grade II or
III, showed fluorescence, and in eight of these cases fluores-
cence was considered useful for resection (Tables 2 and 3).
Notably, the only child without intra-operative tumor fluores-
cence regurgitated the 5-ALA solution immediately after in-
gestion. If ependymoma is suspected, 5-ALA may be a good
technical adjunct to surgery.
On the other hand, pilocytic astrocytomas only showed
useful fluorescence in a minority of cases. Surprisingly, me-
dulloblastomas, which are considered malignant, revealed
useful fluorescence in only one-quarter of the eight available
cases.
Although being only of academic value at this stage, the
single meningiomas and meningeal sarcoma displayed useful
fluorescence. Useful fluorescence in meningiomas resection
has been described in several adult series [11, 13]. These
observations show that “malignancy” or contrast enhance-
ment by themselves do not represent independent factors that
will reliably predict the accumulation of “useful” fluorescence
in pediatric brain tumors. Also, since so far the mode of
application of 5-ALA used in this series is similar to adults,
it remains to be elucidated whether different dosages or timing
Table 4 Multivariate regression analysis of ex ante factors for predicting
useful fluorescence in 76 cases (spinal tumors were omitted); “useful”
was defined as a change of surgical strategy or detection of residual tumor
from visible fluorescence. For multivariate analysis, all covariates were
included with a univariate p<0.4
Characteristic n Useful n (%) Univariate p Multivariate p
76 36 (47.4)
Contrast enhancement
None 3 1 (33.3) 0.333 0.5653
Weak/patchy 29 11 (37.9)
Strong 44 24 (54.4)
Recurrence
Yes 34 18 (52.9) 0.381 0.6193
No 42 18 (42.9)
Location
Supratentorial 53 28 (52.8) 0.125 0.2202
Cerebellar 23 8 (34.8)
Gender
Male 50 24 (48) 0.761 -
Female 26 12 (46.2)
KPS
<80 10 8 (80) 0.0637 0.821
70–80 12 6 (50)
90–100 54 22 (40.7)
Age (years)
<8 19 36.8 0.761 -
9–13 23 52.2
14–16 18 50
>16 16 50
Two spinal cases omitted (spinal lipoma and spinal pilocytic astrocytoma)
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will be more adequate for tumors that showed inconsistent
fluorescence accumulation in this series, e.g., gangliogliomas
or PNETs.
From a practical point of view, a histological diag-
nosis is generally not available prior to definite surgery
(with the exception of previous biopsy). Thus, algo-
rithms are necessary that allow ex ante predictions of
the availability of useful fluorescence. From our analy-
sis, we propose a decision tree based on recursive
partition analysis. This analysis shows children with
supratentorial, strongly contrast-enhancing tumors to
have the greatest potential benefit from 5-ALA, if
histology is unknown and if the timing and dosages
that have been found useful in the adult malignant
glioma population are employed.
In two patients, the occurrence of unspecific fluorescence
in single samples was noted, always weak in nature and
confined to gliosis. Although fluorescence is considered high-
ly predictive in recurrent gliomas with a positive predictive
value of over 95 % [28], weak fluorescence has sometimes
been found in these patients and related to tissues to gliosis
and scarring but not to functional brain. Similar tissue alter-
ations cannot principally be ruled out in recurrent pediatric
brain tumors.
Fig. 4 Decision tree generated from recursive partitioning analysis for ex
ante determination of the likelihood for “usefulness”. Factors: Location;
contrast enhancement on MRI, recurrence status (“useful”=provoking a
change in surgical strategy or helping detect residual tumor; two children
with spinal tumors excluded). There are five terminal nodes based on the
likelihood of “usefulness” of fluorescence after three splits
Table 5 Listing of reported adverse events with histology and fluorescence findings
Age Final histology WHO grade Recurrence Tumor location Adverse events/complications
6 Pilocytic astrocytoma I No Hypothalamic-chiasmatic Cerebral salt wasting, vasospasm with
hemiparesis right side
15 Glial fibrillary astrocytoma II No Supratentorial Resolution of neurological impairment
7 Medulloblastoma IV No Cerebellar Transient posterior fossa syndrome
12 Pilocytic astrocytoma I Yes Supratentorial Complex seizures/absences within first
week post surgery
12 Ependymoma IV Yes Cerebellar Cerebellar neurological deficits
12 Ependymoma III Yes Cerebellar Transient hoarseness
16 Ependymoma II Yes Supratentorial Hygroma
11 Anaplastic oligodendroglioma III Yes Supratentorial Pre existing shunt became infected and
dysfunctional
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Reported complications in this series were few and not
evidently related to the use of 5-ALA, although a standardized
analysis of laboratory values has not been performed. In their
retrospective series of 16 children treated with 5-ALA, Beez
et al. [25] reported a transient increase in liver enzymes, which
has also been reported in adults [29]. In adults, this elevation is
transient and has not been considered an indicator of liver
damage but rather related to metabolism of 5-ALA and its
downstream metabolites.
Given the present data, a future trial designed by our group
in children will only consider intraaxial, strongly contrast-
enhancing supratentorial tumors either in the primary or in
the recurrent setting. We justify the exclusion of children with
posterior fossa tumors in a context of first controlled trial by
the low frequency of useful fluorescence observed in this
group, especially in a first surgery setting without previous
histological diagnosis. In these cases, less than 25 % of
children revealed tumors with useful fluorescence due to the
high incidence of pilocytic astrocytomas in patients with first
surgery. This trial will primarily focus on toxicological safety
and secondarily on the positive predictive value of fluores-
cence for detecting and visualizing tumor. The timing of
administration will be uniform and earlier than found in the
present study, given experimental data available so far for
in vitro childhood brain tumors [26].
Such a study does not rule out the future use of 5-ALA in
entities in which the accumulation of useful fluorescence is
less likely, as suggested by the current data, but only on the
basis of established safety data.
A future randomized study in pediatric patients with a
particular tumor subtype, e.g., glioblastoma with survival as
an endpoint, is unlikely to be designed due to the overall
paucity of these tumors and the established use of 5-ALA in
adult patients.
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